Navio Theragnostics

Navio Theragnostics was a precision medicine company that developed an in vivo microdevice platform for functional drug profiling in oncology. The technology allowed for the simultaneous testing of multiple anti-cancer agents directly within a patient's tumor, providing real-time data on drug efficacy and resistance. By measuring the tumor's response to micro-doses of various therapies, the platform aimed to guide personalized treatment decisions more accurately than genomic profiling alone. The company's approach focused on the functional response of the tumor microenvironment, bypassing the limitations of purely molecular or genetic diagnostics. Navio was acquired by Kinnate Biopharma in 2020 to integrate its diagnostic capabilities with Kinnate's kinase inhibitor pipeline. Following the acquisition, the technology was intended to support the development of targeted therapies by identifying the most responsive patient populations.